Tesla (TSLA) › Analysis

Tesla (TSLA) stock analysis, March 17, 2026: Tesla tests $400 as $30B Terafab plan meets -$4.1B FCF forecast

Published March 17, 2026 · TSLA chart, levels and live analysis

Key Updates

Tesla shares recovered +2.03% to $399.36 since the March 13 report, approaching but not yet reclaiming the critical $400 psychological threshold. The rally was driven by positive investor sentiment surrounding the Terafab Project announcement, which launches in 7 days and represents Tesla's ambitious entry into chip manufacturing. However, this strategic pivot raises significant capital allocation concerns, with UBS estimating initial costs of $30 billion and potential full-scale investments reaching $300 billion, while Wall Street projects Tesla's first negative free cash flow since 2018 at -$4.1 billion for 2026.

Current Trend

Tesla remains in a confirmed downtrend with YTD losses of -11.20%, extending underperformance across all major timeframes: -4.33% over one month and -6.22% over six months. The stock continues to struggle at the $400 resistance level, having failed to maintain above this threshold in recent sessions despite temporary breakouts. Short-term momentum shows marginal improvement with +0.96% daily and +0.03% weekly gains, but this represents consolidation rather than trend reversal. The 6-month decline of -6.22% indicates persistent selling pressure, with the stock unable to establish a sustainable base above critical support levels.

Investment Thesis

The investment thesis centers on Tesla's transformation from an automotive manufacturer into a diversified technology platform spanning autonomous driving, AI infrastructure, robotics, and energy. Bank of America values the autonomous vehicle and robotaxi businesses at $735 billion, more than double the $345 billion attributed to the core EV division, with the robotaxi business alone valued at $422 billion. The thesis assumes Tesla will achieve $1.58 cost per mile at scale versus $3.41 for traditional ride-sharing, capture up to 50% of the global robotaxi market, and grow FSD customers from 1.1 million to 8.7 million by 2030. Additional value drivers include the Optimus humanoid robot segment (valued over $30 billion) and the energy business ($90 billion). However, this thesis requires successful execution across multiple capital-intensive initiatives simultaneously, regulatory approvals in key markets including China and Europe, and sustained investor patience through a multi-year negative free cash flow period.

Thesis Status

The investment thesis faces mounting execution risks as capital requirements escalate beyond initial projections. The Terafab Project announcement adds another capital-intensive initiative requiring $30-300 billion, compounding the already announced $20 billion in 2026 capex for AI and robotaxi development. This represents a significant deviation from the core thesis, as Tesla now pursues vertical integration into semiconductor manufacturing—a highly specialized industry with different competitive dynamics. The regulatory environment remains challenging, with California forcing removal of "Autopilot" branding and 14 robotaxi crashes in Austin since June, raising questions about timeline assumptions for regulatory approvals. The shift to subscription-only FSD at $99/month demonstrates progress in recurring revenue models, but current adoption of 1.1 million customers out of 8.9 million vehicles sold (12.4% penetration) suggests a significant execution gap to reach the 8.7 million target by 2030. The thesis remains intact directionally but faces elevated implementation risks and extended timelines.

Key Drivers

Terafab Chip Manufacturing Initiative: The announcement of the Terafab Project, launching in 7 days, represents Tesla's most ambitious diversification yet. CEO Elon Musk stated that current partners TSMC, Samsung, and Micron cannot meet future AI chip demand, with volume production of the AI5 chip targeted for 2027. UBS estimates initial costs at $30 billion with potential full-scale investment reaching $300 billion.

Capital Expenditure Surge and Free Cash Flow Concerns: Tesla projects 2026 capex exceeding $20 billion excluding Terafab costs, more than double previous levels. Wall Street analysts forecast negative free cash flow of $4.1 billion in 2026, marking the first negative FCF since 2018 as the company enters a capital-intensive expansion phase across multiple fronts simultaneously.

Robotaxi Valuation and Market Expansion: Bank of America assigns 54% of Tesla's total valuation to robotaxi, more than double the 21% for core automotive. Tesla operates in two cities currently with plans to expand to seven additional markets in H1 2026. Morgan Stanley projects 5 million robotaxis on roads by 2035, up from an expected 1,000 by end of 2026, indicating very early-stage deployment.

Regulatory Compliance and Marketing Changes: Tesla avoided a 30-day California sales ban by removing "Autopilot" from marketing materials and discontinuing the feature entirely in the U.S. and Canada. The company now markets FSD as "supervised" technology and shifted to subscription-only pricing at $99/month, eliminating the $8,000 upfront purchase option. This change aligns with Musk's compensation package requirements tied to FSD subscription growth.

Autonomous Driving Safety Concerns: Tesla's Austin robotaxi service experienced 14 crashes since launching in June, highlighting operational challenges in autonomous vehicle deployment. These incidents underscore the gap between current capabilities and the fully autonomous operation required for the robotaxi thesis to materialize at scale.

Technical Analysis

Tesla trades at $399.36, just below the critical $400 psychological resistance that has capped rallies in recent sessions. The stock demonstrated a +2.03% recovery from $391.41 but remains unable to establish sustainable momentum above this key level. The YTD performance of -11.20% places the stock in a confirmed intermediate-term downtrend, with the 6-month decline of -6.22% indicating persistent distribution. Recent price action shows consolidation between $390-$410, forming a narrow trading range after the March 11 surge to $408.33 failed to hold. The one-month decline of -4.33% suggests the path of least resistance remains lower despite short-term stabilization. Volume patterns around the Terafab announcement indicate investor interest but insufficient conviction to drive a sustained breakout. Key support lies at $390, with a break below targeting the $370-$375 zone. Resistance at $400 must be convincingly cleared on strong volume to signal potential trend reversal, with $420-$425 representing the next technical hurdle.

Bull Case

Bear Case

Get a message when the TSLA picture changes — the agent team watches the levels and the news for you.Create a free account

More TSLA analyses